Feed Preview

SETD2 Functions (Keystone)

SETD2 Functions (Keystone) diagram by undefined

Histone methyltransferases (HMTs), as chromatin modifiers, regulate the transcriptomic landscape in normal development as well as in diseases such as cancer. Here is the latest research on SETD2 as a tumor suppressor with actin lysine methyltransferase activity.

Top 20 most recent papers
The Journal of Experimental Medicine

PRDM16 suppresses HIF-targeted gene expression in kidney cancer

The Journal of Experimental MedicineApril 7, 2020
Anirban KunduSunil Sudarshan
3
Signal Transduction and Targeted Therapy

NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F -positive myeloproliferative neoplasm cells

Signal Transduction and Targeted TherapyJanuary 30, 2020
Bruna Alves FenerichFabiola Traina
AMB Express

Bacterial delivery of the anti-tumor azurin-like protein Laz to glioblastoma cells

AMB ExpressMarch 30, 2020
Manar MansourKhaled Abou-Aisha
1
Cancers

Prognostic and Predictive Value of PBRM1 in Clear Cell Renal Cell Carcinoma

CancersDecember 22, 2019
Lucía Carril-AjuriaGuillermo de Velasco
3
Frontiers in Genetics

Systematically Dissecting the Function of RNA-Binding Proteins During Glioma Progression

Frontiers in GeneticsFebruary 13, 2020
Jianjun WangXianzeng Hou
Cell Death & Disease

SETD2 mutation in renal clear cell carcinoma suppress autophagy via regulation of ATG12

Cell Death & DiseaseJanuary 29, 2020
Patricia González-RodríguezBertrand Joseph
7
Journal of Controlled Release : Official Journal of the Controlled Release Society

Local delivery of cardiac stem cells overexpressing HIF-1α promotes angiogenesis and muscular tissue repair in a hind limb ischemia model

Journal of Controlled Release : Official Journal of the Controlled Release SocietyMarch 21, 2020
Xing PeiHuining He
American Journal of Medical Genetics. Part C, Seminars in Medical Genetics

SETD2 related overgrowth syndrome: Presentation of four new patients and review of the literature

American Journal of Medical Genetics. Part C, Seminars in Medical GeneticsOctober 24, 2019
Pauline MarzinValérie Cormier-Daire
4
6
Biochemical and Biophysical Research Communications

Suppression of HIF-1α accumulation by betulinic acid through proteasome activation in hypoxic cervical cancer

Biochemical and Biophysical Research CommunicationsJanuary 18, 2020
Hwee-Jin KimHiroyuki Nakamura

See more papers from this feed

Related Feeds

Aging Genetics (Keystone)

This feed focuses on aging epidemiology and genetic, epigenetic, and proteomic aspects underlying aging, as well as aging- associated biomarkers. Here the latest research in this domain.

Anthracycline Sensitivity & Chromatin (Keystone)

Anthracyclines are used in the treatment of cancer and work by inhibiting topoisomerase II (TOP2). Recent evidence suggests that because DNA accessibility is crucial for TOP2 binding, chromatin regulatory genes should predict anthracycline response. Find the latest research on anthracycline sensitivity and chromatin regulators in this feed.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics Chromatin Complexes (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin complexes and their role in cancer epigenetics.

Cancer Epigenetics and Chemical Tools (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Using novel chemical tools allows us to learn more about these epigenetic changes and how they impact the neoplastic process. Follow this feed to learn more about cancer epigenetics and chemical tools.

Cancer Epigenetics and Chromatin (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin and its role in cancer epigenetics please follow this feed to learn more.

© 2020 Meta ULC. All rights reserved
/feed-previews/setd2-functions-keystone/3343ce29-eb71-4758-afa8-48597b0ffc1d